News
Navigating Risks in Breast Cancer Diagnosis and Treatment
Oct 12, 2015
To identify risks associated with the diagnosis and treatment of breast cancer and provide insights into potential vulnerabilities for providers and patients, Candello and The Doctors Company partnered on a detailed analysis of 562 breast cancer medical malpractice claims from 2009 to 2014 in the Candello data.
Citation for the full-text article:
Greenberg P, Ranum D, Siegal D. Navigating Risk in Breast Cancer Diagnosis and Treatment. PSQH. Oct 12, 2015
Latest News from CRICO
Get all your medmal and patient safety news here.
The Divide Between Breast Density Notification Laws and Evidence-Based Guidelines for Breast Cancer Screening: Legislating Practice.
News
The authors of this JAMA viewpoint discuss the shortfalls of breast density notification laws around the country and advocate for evidence-based care instead.Their research surrounding an evidence-based approach to breast cancer screening is supported by a CRICO grant.
Breast cancer screening in the era of density notification legislation
News
Stemming from breast density notification legislation in Massachusetts effective 2015, researchers of this CRICO-supported study, sought to develop collaborative evidence-based approach to density notification that could be used by practitioners across the state.
Inform Safer Medical Oncology Practice with Lessons from Medical Malpractice Claims
News
The primary goal of analyzing claims from CRICO’s national Candello database was to identify the association between safety incidents in medical oncology practice and systems failures rather than individual provider remediation and to inform potential redesign solutions.
New Open-Source Safety and Quality Discussion Guide for Affiliating Oncology Practices
News
Health system mergers and affiliations pose potential sources of patient safety risk. This editorial published in the Journal of Onclology Practice, discusses how CRICO worked with Ariadne Labs to help provide a structure and a guide that would empower clinical leaders to be more actively involved in an oncology-related merger or affiliation.